In 2011, a large multicenter trial called Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), which planned to enroll 17,200 post myocardial infarction patients, was initiated to determine whether IL-1β inhibition can prevent recurrent myocardial infarction, stroke, and cardiovascular death among stable patients with coronary artery disease who remain at high vascular risk (92). The gene discussed is IL1B; the disease is myocardial infarction.